New Pancreatic Cancer Drugs' Revenue Potential "Limited"

The pancreatic cancer market is set to climb from $855.8 million in 2012 to approximately $1.21 billion by 2019 (a CAGR of 5.1%), says a report from GBI Research. The growth will be fueled by increasing global prevalence of the disease, coupled with the launch at least three new drugs: the recently approved Abraxane (Celgene), and the upcoming TH-302 from Threshold and Merrimack’s MM-398.

However, each of these drugs’ market penetration and subsequent impact on revenues is expected to be limited.

Katie Noon, an analyst for GBI Research, said: ““Potential targeted therapies that have previously been analyzed in clinical trials include vascular endothelial growth factor receptors and epidermal growth factor receptors, but these have had limited success. As a heterogenous disease, it is likely that a combination of targeted therapies will have to be employed to develop an effective treatment for pancreatic cancer.”

While numerous novel agents for targeted therapies are currently being analyzed in the disease’s developmental pipeline, many of these have not been investigated in a clinical setting before now, according to GBI Research.

GBI’s report can be accessed here.